When he was 25, he learned that he had multiple sclerosis. He coped with the disease throughout a long career at several ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Heartland Real Estate Partners founder and chairman David Husman committed $20 million to Nova Southeastern University to ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

Stephen Hawking would have turned 83 years old. Unfortunately, the world-renowned physicist passed away in 2018. Before his ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS.

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...